Clinical trials: Epirubicin
Breast Cancer
Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients
This is a multicentric, open-label,non-randomized concurrent control, 1:1 match,non-inferiority trial that assesses the efficacy and safety of neoadjuvant chemotherapy regimen DC-T and EC-T in breast cancer patients.
- Trial name
- ESNDBCP (NCT03123770)
- Testing
- Pegylated liposomal doxorubicin, Cyclophosphamide, Epirubicin
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Zhejiang University
Triple Negative Breast Cancer
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC.
- Trial name
- NCT01276769
- Testing
- Paclitaxel plus carboplatin, Paclitaxel and epirubicin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy of gemcitabine/cisplatin versus gemcitabine/epirubicin in Stage IIIB/IV NSCLC in terms of response rate and overall survival.
- Trial name
- NCT00154739
- Testing
- Gemcitabine, Cisplatin, Epirubicin
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- National Taiwan University Hospital
Unilateral HER2 Positive Breast Cancer
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy
Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the standard of care in the neoadjuvant setting. In HER2 positive disease trastuzumab is given simultaneously.
- Trial name
- DAFNE (NCT01594177)
- Testing
- Afatinib, Trastuzumab, Paclitaxel
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer
This study will evaluate the efficacy and safety of treatment with oral capecitabine or intravenous (IV) 5-fluorouracil (5-FU), in combination with epirubicin and cyclophosphamide, prior to surgery in participants with breast…
- Trial name
- NCT02846428
- Testing
- 5-Fluorouracil, Capecitabine, Cyclophosphamide
- Where
- 21 sites in France
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Sorafenib
TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma
The study is a multicenter phase III randomized trial. The purpose is to investigate both the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib versus TACE alone for recurrent intermediate…
- Conditions
- Hepatocellular Carcinoma, Sorafenib, Transarterial Chemoembolization
- Trial name
- TREAT (NCT04103398)
- Testing
- TACE+sorafenib, TACE
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Follicular Lymphoma Grade 3A
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.
- Trial name
- PROOF (NCT06961500)
- Testing
- Obinutuzumab, CHOP, Bendamustine
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Sun Yat-sen University
HR+/HER2- Breast Cancer
Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer
This study is a prospective, randomized controlled clinical trial designed to evaluate the efficacy and safety of combining radiotherapy, chemotherapy, and immunotherapy in the neoadjuvant treatment of high-risk HR+/HER2- breast…
- Trial name
- CISN-L (NCT07254858)
- Testing
- Neoadjuvant radiotherapy, Neoadjuvant Chemotherapy (NACT), Immunotherapy (Sintilimab)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization
- Trial name
- NCT07178093
- Testing
- Antrodia cinnamomea
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taichung Tzu Chi Hospital
Sarcoma
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00822848
- Testing
- epirubicin hydrochloride, ifosfamide, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- OHSU Knight Cancer Institute
HER2 Positive Breast Cancer
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
- Trial name
- TROIKA (NCT03013504)
- Testing
- HD201, Herceptin, Docetaxel
- Where
- 15 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 503 people
- Sponsor
- Prestige Biopharma Limited
Breast Cancer
The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC
The purpose of this trial is to compare the 3 years DFS of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer.
- Trial name
- NCT01378533
- Testing
- epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
HER-2 Positive Breast Cancer
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
The study is being conducted to assess the efficacy and safety of anthracycline-containing ddEC-THP intensive regimen and an anthracycline-free TCbHP neoadjuvant therapy for HER2-positive breast cancer
- Trial name
- NCT05871918
- Testing
- TCbHP VS ddEC-THP
- Where
- China
- Volunteers
- 832 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients
This study is a prospective, multicenter, single-arm, exploratory study. 30 patients with locally advanced HR+/HER2- breast cancer who have not received any treatment were recruited to receive apalutamide voraparib combined with…
- Trial name
- NCT07197697
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Cancer Nos Premenopausal
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
The current study is a multicentre, randomized, open (unblended), prospective clinical trial which is sponsored by the researchers.
- Trial name
- NCT01503905
- Testing
- Docetaxel, epirubicin, cyclophosphamide
- Where
- 17 sites in China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and…
- Trial name
- NEOPECX (NCT01234324)
- Testing
- Epirubicin, Cisplatin, Capecitabine, Panitumumab, Epirubicin, Cisplatin, Capecitabine
- Where
- Germany
- Volunteers
- 171 people
- Sponsor
- AIO-Studien-gGmbH
Prostate Cancer
A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine phosphate and celecoxib on PSA and objective response in patients with hormone resistant prostate cancer as well as evaluating the…
- Trial name
- NCT00218205
- Testing
- Epirubicin, Estramustine Phosphate, Celecoxib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Department of Veterans Affairs, New Jersey
Breast Neoplasms
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
Epirubicin is a common chemotherapy medication used in the treatment of breast cancer. However, chemotherapy dosing is calculated based on people's height and weight, which may not be the most accurate way.
- Trial name
- NCT01740271
- Testing
- Epirubicin
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- AHS Cancer Control Alberta
Multiple Myeloma
A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
This is a multicentre; single arm study in subjects with newly diagnosed multiple myeloma. The primary objectives of this study is to assess the effect of bortezomib combination therapy (PAD regimen) followed by ASCT on bone…
- Trial name
- NCT01852799
- Testing
- PAD Followed by ASCT
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Changzheng Hospital
Breast Cancer, Gynecologic Cancer
Food Supplements Based on Nettle and Peppermint to Control Signs and Symptoms Induced by Cancer Therapies
The main purpose of this study is to evaluate the impact of food supplements (herbal remedies) on sign and symptoms induced by cancer therapies: Nettle will be administered for improvement of anemia and fatigue; Peppermint will…
- Trial name
- GALENO 1 (NCT04474951)
- Testing
- Stinging Nettle, Peppermint
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna